TLR7 and neoplasm: These data support the hypothesis that TransCon TLR7/8 Agonist may enable sustained resiquimod exposure in the TME, promoting more efficient anti-tumor activity compared to soluble resiquimod treatment, and may limit peripheral exposure of resiquimod, potentially mitigating systemic adverse events.